A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Semaglutide is a GLP-1 receptor agonist — a lab-made version of a hormone (GLP-1) your intestines already produce naturally after you eat, which signals fullness to your brain and helps regulate blood sugar. Rather than creating an artificial state in your body, Semaglutide amplifies a satiety signal that’s already part of your normal physiology but often isn’t strong enough on its own.
It’s approved under several brand names and forms: Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), Rybelsus (an oral tablet), and as of late 2025/early 2026, an even higher-dose Wegovy HD (7.2 mg) and a 25 mg Wegovy pill. In the large SELECT cardiovascular trial (over 17,000 participants), it also showed a 26% reduction in major cardiac events in adults with established heart disease — a meaningful finding beyond weight management alone.
It’s worth being honest about what Semaglutide is — and isn’t. It doesn’t meaningfully increase how many calories your body burns, and it doesn’t directly improve insulin sensitivity the way some other GLP-1-family medications do. It works almost entirely by reducing how much you eat. That’s exactly why our providers pay close attention to lean muscle mass during treatment — research shows 25–40% of the weight lost on Semaglutide alone can come from muscle rather than fat, which is why adequate protein intake, resistance training, and sometimes complementary hormone or peptide support are built into a well-run protocol rather than treated as optional extras.
Because this pathway reduces food intake, maintaining adequate protein (our reference material recommends 1.2–1.6 g per kg of body weight daily) and overall micronutrient intake — including B12, iron, and zinc — is a genuinely important part of protecting muscle and preventing deficiency while on therapy, not an afterthought.
Semaglutide is FDA-approved for specific indications under brand names such as Ozempic® and Wegovy®. Use outside an approved indication is considered off-label and is determined individually by your provider. One additional note worth flagging honestly: emerging reports link this drug class to anhedonia (a reduced sense of joy or pleasure in daily life) in some patients — something our providers watch for and discuss openly during treatment.
Yes — both are FDA-approved specifically for chronic weight management (in addition to type 2 diabetes), and the clinical trials supporting those approvals documented significant average weight loss in study participants. This is the approved, on-label use of these medications. Individual results vary, and appropriateness is determined through an individualized evaluation with our providers.
Research shows a meaningful portion of weight lost on Semaglutide alone can come from lean muscle rather than fat — which is exactly why our protocols emphasize adequate protein intake, resistance training, and monitoring throughout treatment, rather than treating the medication as a stand-alone solution.
Semaglutide may be included as part of our Metabolic Reset program, which addresses insulin resistance, sleep, and hormones together.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
